AAPL vs ABBV: Which Is the Better Buy?
Side-by-side comparison of Apple Inc. and AbbVie Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-24.
Apple Inc. · Technology
$337.02
+9.9% upside to fair value
Med Conviction
Grade B
High Quality
VS
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
AAPL has more upside to fair value
(+9.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
AAPL |
ABBV |
| Current Price |
$337.02 |
$261.70 |
| Fair Value Estimate |
$370.54 |
$259.04 |
| Upside to Fair Value |
+9.9%
|
-1.0%
|
| Market Cap |
$4,949.9B |
$462.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
29.6x
|
24.8x
|
| Price / Sales |
10.6x
|
7.2x
|
| Price / FCF |
36.2x
|
23.6x
|
| Revenue Growth YoY |
+16.4%
|
+10.2%
|
| Gross Margin |
48.7%
|
71.5%
|
| Operating Margin |
33.2%
|
29.3%
|
| Return on Equity |
137.2%
|
-136.5%
|
| Dividend Yield |
0.31% |
2.61% |
| FCF Yield |
2.76%
|
4.25%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Apple Inc. is a global consumer-electronics and services platform whose hardware lineup (iPhone, Mac, iPad, wearables) and digital ecosystem (App Store, Apple Music, iCloud, Apple Pay, advertising) generated $31.78 of revenue per share and $9.30 of free cash flow per share on a trailing basis, with TTM gross margin of 48.7%, operating margin of 33.2%, net margin of 27.6%, and ROE of 137.2%. Busin…
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Accumulation Zones
| Metric |
AAPL |
ABBV |
| Zone Low |
$277.91 |
$194.28 |
| Zone High |
$314.96 |
$220.18 |
| In Buy Zone? |
No
|
No
|